Global Upper Gastrointestinal (GI) Series Market-Industry Analysis and Forecast (2020-2027) – By Test Type, Application, End Users and Region.

Global Upper Gastrointestinal (GI) Series Market is expected to grow at a CAGR of 4.76% during the forecast period. Global Upper Gastrointestinal (GI) Series Market is expected to reach US$ 3.12 Bn. by 2027. To know about the Research Methodology :- Request Free Sample Report

Global Upper Gastrointestinal (GI) Series Market Definition:

An Upper Gastrointestinal (GI) is a Series of X-rays visualizing the esophagus, stomach, and small intestine after the patient swallow a chalky substance barium solution. A barium swallow is an outpatient procedure is commonly used to determine the cause of pain, swallowing problems, blood stained vomit, and unexplained weight loss that does not require sedation or anesthesia. Approximately 60-70 million people are by major and minor GI disease or disorder. The report study has analyzed revenue impact of covid-19 pandemic on the sales revenue of market leaders, market followers and disrupters in the report and same is reflected in our analysis.

Global Upper Gastrointestinal (GI) Series Market: Market Dynamics:

In the report, under the Market Dynamics Global Upper Gastrointestinal (GI) Series Market covers the exhaustive study and analysis on market size, growth, drivers, restraints, challenges and opportunities faced by the industry. The complete information is based on the qualitative and quantitative assessment through interviews, survey, latest industry news, opportunities, and trends. The global GI services market is driven by changing lifestyle, hospitalization because of the increasing occurrence of GI diseases and gastric cancer, increasing healthcare agencies expenditure and cost-effective method have also subsidized to the growth of the market. Moreover, Growing geriatric population, and increasing government support for the R&D in the market have also affected the growth positively. Each year, more than 100 million people are diagnosed with a GI disorder, resulting in 200 million sick days, 50 million medical visits, 16.9 million days lost from school, 10 million hospitalizations and nearly 200,000 deaths per year However, limited applications of the treatment availability of alternative therapies, the side effect of drugs, lack of awareness regarding treatment in rural areas are some of the factors likely to hamper the growth of the Global Upper Gastrointestinal (GI) Series Market. The global GI series market is expected to grow at a CAGR of 5.4% during the forecasted period 2020-2027

Global Upper Gastrointestinal (GI) Series Market Key Trends and Opportunities Impacting Market Growth:

• Despite having the largest therapeutic areas, many of the (GI) disorder are not well understood and which gives less optimally treatment. Hence, giving Opportunities for development of new, innovative and more cost-effective treatments. • Gastroenterology market is set to expand because of the growing population and increasing pharmaceutical companies that recognize the necessity and significance of developing innovative treatments and advancement of Research and development in Upper Gastrointestinal. • Gastrointestinal Clinical trials activities conducted by Agency, such as FDA, National Gastrointestinal Foundation, in developing newly diagnosed medicines for gastrointestinal disease.

Global Upper Gastrointestinal (GI) Series Market: Market Segmentation:

The report covers the comprehensive analytical segments of the Upper Gastrointestinal (GI) Series Market thereby providing a brief insight into the small and large sector. Esophageal reflux is projected to dominate the largest market at the CAGR of XX %. By application esophageal reflux commonly known as acid reflux one of the largest sub-segments of the GI market. Individual go through persistent acid reflux that is more than twice a week and features by a burning pain, also known as heartburn Proton pump inhibitors are the main pharmaceutical treatment. Regularly More than 60 million Americans are supposed to have acid reflux, causing to frequent hospital admittances. GERD is common in western countries affecting 20-30% population. Up to 10% of patients nearly five million complaints of recurrent pain and heartburn. Followed by irritable bowel syndrome (IBS) and dyspepsia. Based on end-user, Hospitals dominates the largest market during the forecast growth of the market. Hospitals ensuring hygiene and maintaining the clinical trial for safety and efficacy with monitoring health benefit delivers complete treatment and providing professionals care immediately. Along with, surgical services and Approach of 24/7 service. The preliminary examination is adopted effectively improving the quality of life.

Global Upper Gastrointestinal (GI) Series Market: Regional analysis

In terms of region, North America dominant the Global Upper Gastrointestinal (GI) Series Market and was valued at US$ XX Bn in 2019 and is expected to reach a value of US$ XX Bn by 2027, with a CAGR of XX% during the forecast period. The major factors dominating the growth of Global Upper Gastrointestinal (GI) Series Market are existences of well-developed health care agencies and drugs available for the treatment of Global Upper Gastrointestinal in the region with large people suffering for chronic disorder and growing geriatric population. The occurrence rate in adults aged is nearly 60 to 70 besides the only, in the U.S about 20% of people have symptoms every week almost 7% every day. Furthermore, 80 million people worldwide about 24 million of whom live in Europe, suffer from constipation.

Global Upper Gastrointestinal (GI) Series Market Competitive Analysis:

Global Upper Gastrointestinal (GI) is a competitive market as large companies are investing in R&D to launch new products in a cost-effective manner to provides a valuable insight of industry statements of Market and various strategies such as collaborations, expansions, acquisitions, and portfolio, joint ventures, and Cancer to put down the other competitor. Eisai Co., Ltd. company announced its partnership with AJINOMOTO CO.,INC. for the formation of gastrointestinal EA Pharma Co., Ltd. and has launched product used for contrast media. &nbsp. GE Healthcare one of the leading American multinational company in the U.S. Recently company has launch Clariscan, which is a macrocyclic agent and use for effective visualization for abnormalities in the brain, spine and associated tissues. OMNISCAN and VISIPAQUE are the major products. The objective of the report is to present a comprehensive analysis of the Upper Gastrointestinal (GI) Series Market including all the stakeholders of the industry. The past and current status of the industry with forecasted Market size and trends are presented in the report with the analysis of complicated data in simple language. The report covers all the aspects of the industry with a dedicated study of key players that includes Market leaders, followers, and new entrants. PORTER, SVOR, PESTEL analysis with the potential impact of micro-economic factors of the Market have been presented in the report. External as well as internal factors that are supposed to affect the business positively or negatively have been analyzed, which will give a clear futuristic view of the industry to the decision-makers. The report also helps in understanding Upper Gastrointestinal (GI) Series Market dynamics, structure by analyzing the Market segments and projects the Upper Gastrointestinal (GI) Series Market size. Clear representation of competitive analysis of key players By Application, price, financial position, Product portfolio, growth strategies, and regional presence in the Upper Gastrointestinal (GI) Series Market make the report investor’s guide

Scope of the Global Upper Gastrointestinal (GI) Series Market : Inquire before buying

Global Upper Gastrointestinal (GI) Series Market, By Test Type:

• Standard barium upper GI series • Double-contrast upper GI series

Global Upper Gastrointestinal (GI) Series Market, By Application:

• Hiatal hernias • Ulcers • Tumors • Esophageal varices • Esophageal reflux • Strictures • Enteritis • Gastrointestinal dysmotility • Cancer

Global Upper Gastrointestinal (GI) Series Market, By End-Users

• Hospitals • Laboratories • Clinics

Global Upper Gastrointestinal (GI) Series Market, By Region

• North America • Europe • Asia Pacific • Middle East and Africa • Latin America

Global Upper Gastrointestinal (GI) Series Market, By key Players

• GastroIntestinal Endoscopy • GastroIntestinal Specialists • Eisai US • Cadila Pharmaceuticals Limited • PeaceHealth • Purdue Pharma L.P. • Alfa Wassermann • NOVADAQ • Mount Sinai Beth Israel • AstraZeneca • Ironwood Pharmaceuticals • GE, Healthcare • Outpost Medicine • Cook Group • Frequency Therapeutics • Ardelyx • Meridian Bioscience Inc • Second Genome • Arena Pharmaceuticals, Inc • APC Microbiome Institute
Global Upper Gastrointestinal (GI) Series Market 1. Preface 1.1. Report Scope and Market Segmentation 1.2. Research Highlights 1.3. Research Objectives 2. Assumptions and Research Methodology 2.1. Report Assumptions 2.2. Abbreviations 2.3. Research Methodology 2.3.1. Secondary Research 2.3.1.1. Secondary data 2.3.1.2. Secondary Sources 2.3.2. Primary Research 2.3.2.1. Data from Primary Sources 2.3.2.2. Breakdown of Primary Sources 3. Executive Summary: Global Upper Gastrointestinal (GI) Series Market Size, by Market Value (US$ Bn) 4. Market Overview 4.1. Introduction 4.2. Market Indicator 4.2.1. Drivers 4.2.2. Restraints 4.2.3. Opportunities 4.2.4. Challenges 4.3. Porter’s Analysis 4.4. Value Chain Analysis 4.5. Market Risk Analysis 4.6. SWOT Analysis 4.7. Industry Trends and Emerging Technologies 5. Supply Side and Demand Side Indicators 6. Global Upper Gastrointestinal (GI) Series Market Analysis and Forecast 6.1. Global Upper Gastrointestinal (GI) Series Market Size & Y-o-Y Growth Analysis 6.1.1. North America 6.1.2. Europe 6.1.3. Asia Pacific 6.1.4. Middle East & Africa 6.1.5. South America 7. Global Upper Gastrointestinal (GI) Series Market Analysis and Forecast, By Test Type 7.1. Introduction and Definition 7.2. Key Findings 7.3. Global Upper Gastrointestinal (GI) Series Market Value Share Analysis, By Test Type 7.4. Global Upper Gastrointestinal (GI) Series Market Size (US$ Bn) Forecast, By Test Type 7.5. Global Upper Gastrointestinal (GI) Series Market Analysis, By Test Type 7.6. Global Upper Gastrointestinal (GI) Series Market Attractiveness Analysis, By Test Type 8. Global Upper Gastrointestinal (GI) Series Market Analysis and Forecast, By Application 8.1. Introduction and Definition 8.2. Key Findings 8.3. Global Upper Gastrointestinal (GI) Series Market Value Share Analysis, By Application 8.4. Global Upper Gastrointestinal (GI) Series Market Size (US$ Bn) Forecast, By Application 8.5. Global Upper Gastrointestinal (GI) Series Market Analysis, By Application 8.6. Global Upper Gastrointestinal (GI) Series Market Attractiveness Analysis, By Application 9. Global Upper Gastrointestinal (GI) Series Market Analysis and Forecast, By End-Users 9.1. Introduction and Definition 9.2. Key Findings 9.3. Global Upper Gastrointestinal (GI) Series Market Value Share Analysis, By End-Users 9.4. Global Upper Gastrointestinal (GI) Series Market Size (US$ Bn) Forecast, By End-Users 9.5. Global Upper Gastrointestinal (GI) Series Market Analysis, By End-Users 9.6. Global Upper Gastrointestinal (GI) Series Market Attractiveness Analysis, By End-Users 10. Global Upper Gastrointestinal (GI) Series Market Analysis, by Region 10.1. Global Upper Gastrointestinal (GI) Series Market Value Share Analysis, by Region 10.2. Global Upper Gastrointestinal (GI) Series Market Size (US$ Bn) Forecast, by Region 10.3. Global Upper Gastrointestinal (GI) Series Market Attractiveness Analysis, by Region 11. North America Upper Gastrointestinal (GI) Series Market Analysis 11.1. Key Findings 11.2. North America Upper Gastrointestinal (GI) Series Market Overview 11.3. North America Upper Gastrointestinal (GI) Series Market Value Share Analysis, By Test Type 11.4. North America Upper Gastrointestinal (GI) Series Market Forecast, By Test Type 11.4.1. Standard barium upper GI series 11.4.2. Double-contrast upper GI series 11.5. North America Upper Gastrointestinal (GI) Series Market Value Share Analysis, By Application 11.6. North America Upper Gastrointestinal (GI) Series Market Forecast, By Application 11.6.1. Hiatal hernias 11.6.2. Ulcers 11.6.3. Tumors 11.6.4. Esophageal varices 11.6.5. Esophageal reflux 11.6.6. Strictures 11.6.7. Enteritis 11.6.8. Gastrointestinal dysmotility 11.6.9. Cancer 11.7. North America Upper Gastrointestinal (GI) Series Market Value Share Analysis, By End-Users 11.8. North America Upper Gastrointestinal (GI) Series Market Forecast, By End-Users 11.8.1. Hospitals 11.8.2. Laboratories 11.8.3. Clinics 11.9. North America Upper Gastrointestinal (GI) Series Market Value Share Analysis, by Country 11.10. North America Upper Gastrointestinal (GI) Series Market Forecast, by Country 11.10.1. U.S. 11.10.2. Canada 11.11. North America Upper Gastrointestinal (GI) Series Market Analysis, by Country 11.12. U.S. Upper Gastrointestinal (GI) Series Market Forecast, By Test Type 11.12.1. Standard barium upper GI series 11.12.2. Double-contrast upper GI series 11.13. U.S. Upper Gastrointestinal (GI) Series Market Forecast, By Application 11.13.1. Hiatal hernias 11.13.2. Ulcers 11.13.3. Tumors 11.13.4. Esophageal varices 11.13.5. Esophageal reflux 11.13.6. Strictures 11.13.7. Enteritis 11.13.8. Gastrointestinal dysmotility 11.13.9. Cancer 11.14. U.S. Upper Gastrointestinal (GI) Series Market Forecast, By End-Users 11.14.1. Hospitals 11.14.2. Laboratories 11.14.3. Clinics 11.15. Canada Upper Gastrointestinal (GI) Series Market Forecast, By Test Type 11.15.1. Standard barium upper GI series 11.15.2. Double-contrast upper GI series 11.16. Canada Upper Gastrointestinal (GI) Series Market Forecast, By Application 11.16.1. Hiatal hernias 11.16.2. Ulcers 11.16.3. Tumors 11.16.4. Esophageal varices 11.16.5. Esophageal reflux 11.16.6. Strictures 11.16.7. Enteritis 11.16.8. Gastrointestinal dysmotility 11.16.9. Cancer 11.17. Canada Upper Gastrointestinal (GI) Series Market Forecast, By End-Users 11.17.1. Hospitals 11.17.2. Laboratories 11.17.3. Clinics 11.18. North America Upper Gastrointestinal (GI) Series Market Attractiveness Analysis 11.18.1. By Test Type 11.18.2. By Application 11.18.3. By End-Users 11.19. PEST Analysis 11.20. Key Trends 11.21. Key Developments 12. Europe Upper Gastrointestinal (GI) Series Market Analysis 12.1. Key Findings 12.2. Europe Upper Gastrointestinal (GI) Series Market Overview 12.3. Europe Upper Gastrointestinal (GI) Series Market Value Share Analysis, By Test Type 12.4. Europe Upper Gastrointestinal (GI) Series Market Forecast, By Test Type 12.4.1. Standard barium upper GI series 12.4.2. Double-contrast upper GI series 12.5. Europe Upper Gastrointestinal (GI) Series Market Value Share Analysis, By Application 12.6. Europe Upper Gastrointestinal (GI) Series Market Forecast, By Application 12.6.1. Hiatal hernias 12.6.2. Ulcers 12.6.3. Tumors 12.6.4. Esophageal varices 12.6.5. Esophageal reflux 12.6.6. Strictures 12.6.7. Enteritis 12.6.8. Gastrointestinal dysmotility 12.6.9. Cancer 12.7. Europe Upper Gastrointestinal (GI) Series Market Value Share Analysis, By End-Users 12.8. Europe Upper Gastrointestinal (GI) Series Market Forecast, By End-Users 12.8.1. Hospitals 12.8.2. Laboratories 12.8.3. Clinics 12.9. Europe Upper Gastrointestinal (GI) Series Market Value Share Analysis, by Country 12.10. Europe Upper Gastrointestinal (GI) Series Market Forecast, by Country 12.10.1. Germany 12.10.2. U.K. 12.10.3. France 12.10.4. Italy 12.10.5. Spain 12.10.6. Rest of Europe 12.11. Europe Upper Gastrointestinal (GI) Series Market Analysis, by Country 12.12. Germany Upper Gastrointestinal (GI) Series Market Forecast, By Test Type 12.12.1. Standard barium upper GI series 12.12.2. Double-contrast upper GI series 12.13. Germany Upper Gastrointestinal (GI) Series Market Forecast, By Application 12.13.1. Hiatal hernias 12.13.2. Ulcers 12.13.3. Tumors 12.13.4. Esophageal varices 12.13.5. Esophageal reflux 12.13.6. Strictures 12.13.7. Enteritis 12.13.8. Gastrointestinal dysmotility 12.13.9. Cancer 12.14. Germany Upper Gastrointestinal (GI) Series Market Forecast, By End-Users 12.14.1. Hospitals 12.14.2. Laboratories 12.14.3. Clinics 12.15. U.K. Upper Gastrointestinal (GI) Series Market Forecast, By Test Type 12.15.1. Standard barium upper GI series 12.15.2. Double-contrast upper GI series 12.16. U.K. Upper Gastrointestinal (GI) Series Market Forecast, By Application 12.16.1. Hiatal hernias 12.16.2. Ulcers 12.16.3. Tumors 12.16.4. Esophageal varices 12.16.5. Esophageal reflux 12.16.6. Strictures 12.16.7. Enteritis 12.16.8. Gastrointestinal dysmotility 12.16.9. Cancer 12.17. U.K. Upper Gastrointestinal (GI) Series Market Forecast, By End-Users 12.17.1. Hospitals 12.17.2. Laboratories 12.17.3. Clinics 12.18. France Upper Gastrointestinal (GI) Series Market Forecast, By Test Type 12.18.1. Standard barium upper GI series 12.18.2. Double-contrast upper GI series 12.19. France Upper Gastrointestinal (GI) Series Market Forecast, By Application 12.19.1. Hiatal hernias 12.19.2. Ulcers 12.19.3. Tumors 12.19.4. Esophageal varices 12.19.5. Esophageal reflux 12.19.6. Strictures 12.19.7. Enteritis 12.19.8. Gastrointestinal dysmotility 12.19.9. Cancer 12.20. France Upper Gastrointestinal (GI) Series Market Forecast, By End-Users 12.20.1. Hospitals 12.20.2. Laboratories 12.20.3. Clinics 12.21. Italy Upper Gastrointestinal (GI) Series Market Forecast, By Test Type 12.21.1. Standard barium upper GI series 12.21.2. Double-contrast upper GI series 12.22. Italy Upper Gastrointestinal (GI) Series Market Forecast, By Application 12.22.1. Hiatal hernias 12.22.2. Ulcers 12.22.3. Tumors 12.22.4. Esophageal varices 12.22.5. Esophageal reflux 12.22.6. Strictures 12.22.7. Enteritis 12.22.8. Gastrointestinal dysmotility 12.22.9. Cancer 12.23. Italy Upper Gastrointestinal (GI) Series Market Forecast, By End-Users 12.23.1. Hospitals 12.23.2. Laboratories 12.23.3. Clinics 12.24. Spain Upper Gastrointestinal (GI) Series Market Forecast, By Test Type 12.24.1. Standard barium upper GI series 12.24.2. Double-contrast upper GI series 12.25. Spain Upper Gastrointestinal (GI) Series Market Forecast, By Application 12.25.1. Hiatal hernias 12.25.2. Ulcers 12.25.3. Tumors 12.25.4. Esophageal varices 12.25.5. Esophageal reflux 12.25.6. Strictures 12.25.7. Enteritis 12.25.8. Gastrointestinal dysmotility 12.25.9. Cancer 12.26. Spain Upper Gastrointestinal (GI) Series Market Forecast, By End-Users 12.26.1. Hospitals 12.26.2. Laboratories 12.26.3. Clinics 12.27. Rest of Europe Upper Gastrointestinal (GI) Series Market Forecast, By Test Type 12.27.1. Standard barium upper GI series 12.27.2. Double-contrast upper GI series 12.28. Rest of Europe Upper Gastrointestinal (GI) Series Market Forecast, By Application 12.28.1. Hiatal hernias 12.28.2. Ulcers 12.28.3. Tumors 12.28.4. Esophageal varices 12.28.5. Esophageal reflux 12.28.6. Strictures 12.28.7. Enteritis 12.28.8. Gastrointestinal dysmotility 12.28.9. Cancer 12.29. Rest Of Europe Upper Gastrointestinal (GI) Series Market Forecast, By End-Users 12.29.1. Hospitals 12.29.2. Laboratories 12.29.3. Clinics 12.30. Europe Upper Gastrointestinal (GI) Series Market Attractiveness Analysis 12.30.1. By Test Type 12.30.2. By Application 12.30.3. By End-Users 12.31. PEST Analysis 12.32. Key Trends 12.33. Key Developments 13. Asia Pacific Upper Gastrointestinal (GI) Series Market Analysis 13.1. Key Findings 13.2. Asia Pacific Upper Gastrointestinal (GI) Series Market Overview 13.3. Asia Pacific Upper Gastrointestinal (GI) Series Market Value Share Analysis, By Test Type 13.4. Asia Pacific Upper Gastrointestinal (GI) Series Market Forecast, By Test Type 13.4.1. Standard barium upper GI series 13.4.2. Double-contrast upper GI series 13.5. Asia Pacific Upper Gastrointestinal (GI) Series Market Value Share Analysis, By Application 13.6. Asia Pacific Upper Gastrointestinal (GI) Series Market Forecast, By Application 13.6.1. Hiatal hernias 13.6.2. Ulcers 13.6.3. Tumors 13.6.4. Esophageal varices 13.6.5. Esophageal reflux 13.6.6. Strictures 13.6.7. Enteritis 13.6.8. Gastrointestinal dysmotility 13.6.9. Cancer 13.7. Asia Pacific Upper Gastrointestinal (GI) Series Market Value Share Analysis, By End-Users 13.8. Asia Pacific Upper Gastrointestinal (GI) Series Market Forecast, By End-Users 13.8.1. Hospitals 13.8.2. Laboratories 13.8.3. Clinics 13.9. Asia Pacific Upper Gastrointestinal (GI) Series Market Value Share Analysis, by Country 13.10. Asia Pacific Upper Gastrointestinal (GI) Series Market Forecast, by Country 13.10.1. China 13.10.2. India 13.10.3. Japan 13.10.4. ASEAN 13.10.5. Rest of Asia Pacific 13.11. Asia Pacific Upper Gastrointestinal (GI) Series Market Analysis, by Country 13.12. China Upper Gastrointestinal (GI) Series Market Forecast, By Test Type 13.12.1. Standard barium upper GI series 13.12.2. Double-contrast upper GI series 13.13. China Upper Gastrointestinal (GI) Series Market Forecast, By Application 13.13.1. Hiatal hernias 13.13.2. Ulcers 13.13.3. Tumors 13.13.4. Esophageal varices 13.13.5. Esophageal reflux 13.13.6. Strictures 13.13.7. Enteritis 13.13.8. Gastrointestinal dysmotility 13.13.9. Cancer 13.14. China Upper Gastrointestinal (GI) Series Market Forecast, By End-Users 13.14.1. Hospitals 13.14.2. Laboratories 13.14.3. Clinics 13.15. India Upper Gastrointestinal (GI) Series Market Forecast, By Test Type 13.15.1. Standard barium upper GI series 13.15.2. Double-contrast upper GI series 13.16. India Upper Gastrointestinal (GI) Series Market Forecast, By Application 13.16.1. Hiatal hernias 13.16.2. Ulcers 13.16.3. Tumors 13.16.4. Esophageal varices 13.16.5. Esophageal reflux 13.16.6. Strictures 13.16.7. Enteritis 13.16.8. Gastrointestinal dysmotility 13.16.9. Cancer 13.17. India Upper Gastrointestinal (GI) Series Market Forecast, By End-Users 13.17.1. Hospitals 13.17.2. Laboratories 13.17.3. Clinics 13.18. Japan Upper Gastrointestinal (GI) Series Market Forecast, By Test Type 13.18.1. Standard barium upper GI series 13.18.2. Double-contrast upper GI series 13.19. Japan Upper Gastrointestinal (GI) Series Market Forecast, By Application 13.19.1. Hiatal hernias 13.19.2. Ulcers 13.19.3. Tumors 13.19.4. Esophageal varices 13.19.5. Esophageal reflux 13.19.6. Strictures 13.19.7. Enteritis 13.19.8. Gastrointestinal dysmotility 13.19.9. Cancer 13.20. Japan Upper Gastrointestinal (GI) Series Market Forecast, By End-Users 13.20.1. Hospitals 13.20.2. Laboratories 13.20.3. Clinics 13.21. ASEAN Upper Gastrointestinal (GI) Series Market Forecast, By Test Type 13.21.1. Standard barium upper GI series 13.21.2. Double-contrast upper GI series 13.22. ASEAN Upper Gastrointestinal (GI) Series Market Forecast, By Application 13.22.1. Hiatal hernias 13.22.2. Ulcers 13.22.3. Tumors 13.22.4. Esophageal varices 13.22.5. Esophageal reflux 13.22.6. Strictures 13.22.7. Enteritis 13.22.8. Gastrointestinal dysmotility 13.22.9. Cancer 13.23. ASEAN Upper Gastrointestinal (GI) Series Market Forecast, By End-Users 13.23.1. Hospitals 13.23.2. Laboratories 13.23.3. Clinics 13.24. Rest of Asia Pacific Upper Gastrointestinal (GI) Series Market Forecast, By Test Type 13.24.1. Standard barium upper GI series 13.24.2. Double-contrast upper GI series 13.25. Rest of Asia Pacific Upper Gastrointestinal (GI) Series Market Forecast, By Application 13.25.1. Hiatal hernias 13.25.2. Ulcers 13.25.3. Tumors 13.25.4. Esophageal varices 13.25.5. Esophageal reflux 13.25.6. Strictures 13.25.7. Enteritis 13.25.8. Gastrointestinal dysmotility 13.25.9. Cancer 13.26. Rest of Asia Pacific Upper Gastrointestinal (GI) Series Market Forecast, By End-Users 13.26.1. Hospitals 13.26.2. Laboratories 13.26.3. Clinics 13.27. Asia Pacific Upper Gastrointestinal (GI) Series Market Attractiveness Analysis 13.27.1. By Test Type 13.27.2. By Application 13.27.3. By End-Users 13.28. PEST Analysis 13.29. Key Trends 13.30. Key Developments 14. Middle East & Africa Upper Gastrointestinal (GI) Series Market Analysis 14.1. Key Findings 14.2. Middle East & Africa Upper Gastrointestinal (GI) Series Market Overview 14.3. Middle East & Africa Upper Gastrointestinal (GI) Series Market Value Share Analysis, By Test Type 14.4. Middle East & Africa Upper Gastrointestinal (GI) Series Market Forecast, By Test Type 14.4.1. Standard barium upper GI series 14.4.2. Double-contrast upper GI series 14.5. Middle East & Africa Upper Gastrointestinal (GI) Series Market Value Share Analysis, By Application 14.6. Middle East & Africa Upper Gastrointestinal (GI) Series Market Forecast, By Application 14.6.1. Hiatal hernias 14.6.2. Ulcers 14.6.3. Tumors 14.6.4. Esophageal varices 14.6.5. Esophageal reflux 14.6.6. Strictures 14.6.7. Enteritis 14.6.8. Gastrointestinal dysmotility 14.6.9. Cancer 14.7. Middle East & Africa Upper Gastrointestinal (GI) Series Market Value Share Analysis, By End-Users 14.8. Middle East & Africa Upper Gastrointestinal (GI) Series Market Forecast, By End-Users 14.8.1. Hospitals 14.8.2. Laboratories 14.8.3. Clinics 14.9. Middle East & Africa Upper Gastrointestinal (GI) Series Market Value Share Analysis, by Country 14.10. Middle East & Africa Upper Gastrointestinal (GI) Series Market Forecast, by Country 14.10.1. GCC 14.10.2. South Africa 14.10.3. Rest of Middle East & Africa 14.11. Middle East & Africa Upper Gastrointestinal (GI) Series Market Analysis, by Country 14.12. GCC Upper Gastrointestinal (GI) Series Market Forecast, By Test Type 14.12.1. Standard barium upper GI series 14.12.2. Double-contrast upper GI series 14.13. GCC Upper Gastrointestinal (GI) Series Market Forecast, By Application 14.13.1. Hiatal hernias 14.13.2. Ulcers 14.13.3. Tumors 14.13.4. Esophageal varices 14.13.5. Esophageal reflux 14.13.6. Strictures 14.13.7. Enteritis 14.13.8. Gastrointestinal dysmotility 14.13.9. Cancer 14.14. GCC Upper Gastrointestinal (GI) Series Market Forecast, By End-Users 14.14.1. Hospitals 14.14.2. Laboratories 14.14.3. Clinics 14.15. South Africa Upper Gastrointestinal (GI) Series Market Forecast, By Test Type 14.15.1. Standard barium upper GI series 14.15.2. Double-contrast upper GI series 14.16. South Africa Upper Gastrointestinal (GI) Series Market Forecast, By Application 14.16.1. Hiatal hernias 14.16.2. Ulcers 14.16.3. Tumors 14.16.4. Esophageal varices 14.16.5. Esophageal reflux 14.16.6. Strictures 14.16.7. Enteritis 14.16.8. Gastrointestinal dysmotility 14.16.9. Cancer 14.17. South Africa Upper Gastrointestinal (GI) Series Market Forecast, By End-Users 14.17.1. Hospitals 14.17.2. Laboratories 14.17.3. Clinics 14.18. Rest of Middle East & Africa Upper Gastrointestinal (GI) Series Market Forecast, By Test Type 14.18.1. Standard barium upper GI series 14.18.2. Double-contrast upper GI series 14.19. Rest of Middle East & Africa Upper Gastrointestinal (GI) Series Market Forecast, By Application 14.19.1. Hiatal hernias 14.19.2. Ulcers 14.19.3. Tumors 14.19.4. Esophageal varices 14.19.5. Esophageal reflux 14.19.6. Strictures 14.19.7. Enteritis 14.19.8. Gastrointestinal dysmotility 14.19.9. Cancer 14.20. Middle East & Africa Upper Gastrointestinal (GI) Series Market Forecast, By End-Users 14.20.1. Hospitals 14.20.2. Laboratories 14.20.3. Clinics 14.21. Middle East & Africa Upper Gastrointestinal (GI) Series Market Attractiveness Analysis 14.21.1. By Test Type 14.21.2. By Application 14.21.3. By End-Users 14.22. PEST Analysis 14.23. Key Trends 14.24. Key Developments 15. South America Upper Gastrointestinal (GI) Series Market Analysis 15.1. Key Findings 15.2. South America Upper Gastrointestinal (GI) Series Market Overview 15.3. South America Upper Gastrointestinal (GI) Series Market Value Share Analysis, By Test Type 15.4. South America Upper Gastrointestinal (GI) Series Market Forecast, By Test Type 15.4.1. Standard barium upper GI series 15.4.2. Double-contrast upper GI series 15.5. South America Upper Gastrointestinal (GI) Series Market Value Share Analysis, By Application 15.6. South America Upper Gastrointestinal (GI) Series Market Forecast, By Application 15.6.1. Hiatal hernias 15.6.2. Ulcers 15.6.3. Tumors 15.6.4. Esophageal varices 15.6.5. Esophageal reflux 15.6.6. Strictures 15.6.7. Enteritis 15.6.8. Gastrointestinal dysmotility 15.6.9. Cancer 15.7. South America Upper Gastrointestinal (GI) Series Market Value Share Analysis, By End-Users 15.8. South America Upper Gastrointestinal (GI) Series Market Forecast, By End-Users 15.8.1. Hospitals 15.8.2. Laboratories 15.8.3. Clinics 15.9. South America Upper Gastrointestinal (GI) Series Market Value Share Analysis, by Country 15.10. South America Upper Gastrointestinal (GI) Series Market Forecast, by Country 15.10.1. Brazil 15.10.2. Mexico 15.10.3. Rest of South America 15.11. South America Upper Gastrointestinal (GI) Series Market Analysis, by Country 15.12. Brazil Upper Gastrointestinal (GI) Series Market Forecast, By Test Type 15.12.1. Standard barium upper GI series 15.12.2. Double-contrast upper GI series 15.13. Brazil Upper Gastrointestinal (GI) Series Market Forecast, By Application 15.13.1. Hiatal hernias 15.13.2. Ulcers 15.13.3. Tumors 15.13.4. Esophageal varices 15.13.5. Esophageal reflux 15.13.6. Strictures 15.13.7. Enteritis 15.13.8. Gastrointestinal dysmotility 15.13.9. Cancer 15.14. Brazil Upper Gastrointestinal (GI) Series Market Forecast, By End-Users 15.14.1. Hospitals 15.14.2. Laboratories 15.14.3. Clinics 15.15. Mexico Upper Gastrointestinal (GI) Series Market Forecast, By Test Type 15.15.1. Standard barium upper GI series 15.15.2. Double-contrast upper GI series 15.16. Mexico Upper Gastrointestinal (GI) Series Market Forecast, By Application 15.16.1. Hiatal hernias 15.16.2. Ulcers 15.16.3. Tumors 15.16.4. Esophageal varices 15.16.5. Esophageal reflux 15.16.6. Strictures 15.16.7. Enteritis 15.16.8. Gastrointestinal dysmotility 15.16.9. Cancer 15.17. Mexico Upper Gastrointestinal (GI) Series Market Forecast, By End-Users 15.17.1. Hospitals 15.17.2. Laboratories 15.17.3. Clinics 15.18. Rest of South America Upper Gastrointestinal (GI) Series Market Forecast, By Test Type 15.18.1. Standard barium upper GI series 15.18.2. Double-contrast upper GI series 15.19. Rest of South America Upper Gastrointestinal (GI) Series Market Forecast, By Application 15.19.1. Hiatal hernias 15.19.2. Ulcers 15.19.3. Tumors 15.19.4. Esophageal varices 15.19.5. Esophageal reflux 15.19.6. Strictures 15.19.7. Enteritis 15.19.8. Gastrointestinal dysmotility 15.19.9. Cancer 15.20. Cancer Rest of South America Upper Gastrointestinal (GI) Series Market Forecast, By End-Users 15.20.1. Hospitals 15.20.2. Laboratories 15.20.3. Clinics 15.21. South America Upper Gastrointestinal (GI) Series Market Attractiveness Analysis 15.21.1. By Test Type 15.21.2. By Application 15.21.3. By End-Users 15.22. PEST Analysis 15.23. Key Trends 15.24. Key Developments 16. Company Profiles 16.1. Market Share Analysis, by Company 16.2. Competition Matrix 16.2.1. Competitive Benchmarking of key players by price, presence, Market share, Applications and R&D investment 16.2.2. New Product Launches and Product Enhancements 16.2.3. Market Consolidation 16.2.3.1. M&A by Regions, Investment and Applications 16.2.3.2. M&A Key Players, Forward Integration and Backward 16.2.3.3. Integration 16.3. Company Profiles: Key Players 16.3.1. GastroIntestinal Endoscopy 16.3.1.1. Company Overview 16.3.1.2. Financial Overview 16.3.1.3. Product Portfolio 16.3.1.4. Business Strategy 16.3.1.5. Recent Developments 16.3.1.6. Development Footprint 16.3.2. GastroIntestinal Specialists 16.3.3. Eisai US 16.3.4. Cadila Pharmaceuticals Limited 16.3.5. PeaceHealth 16.3.6. Purdue Pharma L.P. 16.3.7. Alfa Wassermann 16.3.8. NOVADAQ 16.3.9. Mount Sinai Beth Israel 16.3.10. AstraZeneca 16.3.11. Ironwood Pharmaceuticals 16.3.12. GE, Healthcare 16.3.13. Outpost Medicine 16.3.14. Cook Group 16.3.15. Frequency Therapeutics 16.3.16. Ardelyx 16.3.17. Meridian Bioscience Inc 16.3.18. Second Genome 16.3.19. Arena Pharmaceuticals, Inc 16.3.20. APC Microbiome Institute 17. Primary Key Insights

About This Report

Report ID 54133
Category Healthcare
Published Date March 2020
Updated Date
Contact Us